The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines

Breast Cancer Research and Treatment

Volumn 107, Issue 3, 2008, Pages 443-450

  Dranitsaris, George ^a   Rayson, Daniel ^b   Vincent, Mark ^c   Chang, Jose ^d   Gelmon, Karen ^e   Sandor, David ^f,g   Reardon, Greg ^h  

^a Queen Elizabeth II Health Sciences Centre ^*  (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

^d Durham Regional Cancer Centre   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f MERCK RESEARCH LABORATORIES   (United States)

^g Touro College and University System   (United States)

^h Informagenics LLC   (United States)

Author keywords

Anthracyclines; Breast cancer; Cardiac toxicity; Doxorubicin; Prediction; Risk

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HEART; HEART DISEASES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 38649099422     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9803-5     Document Type: Article

References (28)

1. Bonadonna G, Brusamolino E, Valagussa P et al (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410
2. Levine MN Trudeau M, Charbonneau F et al (2005) Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6:886-898
3. Bergh J, Jonsson PE, Glimelius B et al (2001) A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 40:253-281
4. Chan S, Friedrichs K, Noel D et al (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354
5. Paridaens R, Biganzoli L, Bruning P et al (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18:724-733
6. Sledge GW, Neuberg D, Bernardo P et al (2003) Phase III trial of doxuribicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer. J Clin Oncol 21:588-592
7. Pritchard KI, Shepherd LE, O'Malley FP et al (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111
8. Jensen BV (2006) Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 33(3 Suppl 8):S15-S21
9. Jackson JA, Reeves JP, Muntz KH et al (1984) Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. Am J Pathol 117:140-153
10. Myers CE, McGuire WP, Liss RH et al (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumour response. Science 197:165-167
11. Singal PK, Iliskovic N (1998) Doxorubicin induced cardiomyopathy. N Engl J Med 339:900-905
12. Elliott P (2006) Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 33(3 Suppl 8):S2-S7
13. O'Brien ME, Wigler N, Inbar M et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440-449
14. Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263-302
15. George SL (1988) Identification and assessment of prognostic factors. Semin Oncol 15:462-471
16. Allison PD (1999) Logistic regression using the SAS system: theory and application, Chapter 8. SAS Institute Inc., Cary, NC, pp 179-216
17. Steyerberg EW, Eijkemans MJ, Harrell FE Jr et al (2001) Prognostic modeling with logistic regression analysis: in search of sensible strategies in small data sets. Med Decis Making 21:45-56
18. Steyerberg EW, Harrell FE Jr, Borsboom GJ et al (2001) Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54:774-781
19. Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29-36
20. McNeil BJ, Hanley JA (1984) Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decis Making 4:137-150
21. Doyle JJ, Neugut AI, Jacobson JS et al (2005) Chemotherapy and cardiotoxicity in older cancer patients. A population-based study. J Clin Oncol 23:8597-8605
22. Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K (2000) Anthracycline induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention. A review of the literature. Med Sci Monit 6:411-420
23. Wong CY, O'Moore-Sullivan T, Leano R et al (2004) Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 110:3081-3087
24. Di Bello V, Santini F, Di Cori A et al (2006) Obesity cardiomyopathy: is it a reality? An ultrasonic tissue characterization study. J Am Soc Echocardiogr 19:1063-1071
25. Sabel MS, Levine EG, Hurd T et al (2001) Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy?. Am J Clin Oncol 24:425-428
26. Jensem BV, Skovsgaard T, Nielsen SL (2002) Functional monitoring or anthracycline cardiotoxicity: a prospective, blinded, long term observational study of outcome in 120 patients. Ann Oncol 13:699-709
27. Katz MH (2003) Multivariable analysis: a primer for readers of the medical literature. Ann Intern Med 138:644-650
28. Perez EA, Suman VJ, Davidson NE et al (2004) Effect of doxorubicin plus cyclophospamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant trial. J Clin Oncol 22:3700-3704